awmsg logo



sofosbuvir (Sovaldi®)


Reference No. 3568

Publication date:
12/12/2017


Appraisal information

sofosbuvir (Sovaldi®) 400 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 08/12/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, sofosbuvir (Sovaldi®) cannot be endorsed for use within NHS Wales for use in combination with other medicinal products for the treatment of chronic hepatitis C in adolescents aged 12 to < 18 years.
Statement of Advice (SOA)
Download